Aggregate citation datasets tell you what is common across the whole industry. They do not tell you what a firm making the same product, on the same kind of process, at roughly your own scale, just got cited for last quarter, and that is often the more useful comparison, because it is close enough to your own operation that “it would not happen here” is a harder claim to make. This worksheet builds a defensible peer roster and turns each peer’s public enforcement history into the same applicability question the rest of the regulatory intelligence program already asks: do we have this gap too. Replace every <<FILL: ...>> placeholder. Do not name your own company’s real peers, suppliers, or any confidential business relationship in a document that leaves your quality system; use role-based descriptors as shown in the specimen. A filled specimen follows.
Why peer selection needs a rule, not a guess
An unscoped peer list turns into either a handful of firms someone remembers reading about, which biases toward whoever made headlines, or an unmanageable list of every firm in the industry, which nobody actually reads. Select on characteristics that predict a shared citation profile, not on name recognition.
Worksheet control
| Field | Entry |
|---|---|
| Worksheet reference | <<FILL: BMK-YYYY-nnn>> |
| Parent SOP | <<FILL: SOP-ID for the RI program>> |
| Performed by / date | <<FILL>> |
| Roster review cycle | <<FILL: e.g. annual, or when the product portfolio changes>> |
Section A: Peer selection criteria
Score candidate firms against these dimensions before adding them to the roster. A firm does not need to match on every dimension, but the rationale for including a partial match should be written down, not assumed.
| Dimension | Why it matters | This firm matches? |
|---|---|---|
| Product type / modality | Sterile injectable, oral solid, biologic, cell and gene therapy, and combination-product operations each draw a different citation profile | <<FILL: Yes/No/Partial>> |
| Manufacturing model | Own-site manufacturer vs. CDMO-reliant, single-site vs. multi-site | <<FILL>> |
| Approximate scale | Batch volume and site count shape which controls (automation, staffing depth) are realistic to expect | <<FILL>> |
| Jurisdictions inspected | A US-only peer tells you little about your EU exposure and vice versa | <<FILL>> |
| Public inspection history available | A firm with no public 483s or warning letters on record cannot be benchmarked from public sources alone | <<FILL>> |
Section B: Peer roster
List the firms selected, using role-based descriptors rather than assuming everyone reading this document already knows who they are. Keep the roster to a number you can actually track each quarter; four to eight peers is usually more sustainable than twenty.
| Peer ref | Descriptor (modality, model, scale) | Jurisdictions tracked | Rationale for inclusion | Added / last reviewed |
|---|---|---|---|---|
<<FILL: Peer A>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
<<FILL: Peer B>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
Section C: Enforcement history per peer
One row per public enforcement item found for a roster peer during the review period. Pull from the sources listed in the Regulatory Intelligence Signal-Source Monitoring Matrix.
| Peer ref | Document type | Date | Cited regulation | Failure theme | Escalation outcome | Close-out status (if WL) |
|---|---|---|---|---|---|---|
<<FILL>> | <<FILL: 483 / WL / EudraGMDP NC>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL: closed / open / N/A>> |
Section D: Gap comparison against our own operation
This is the section that turns a peer’s citation into a decision, not just an interesting read. For each distinct theme found in Section C, answer the same applicability question the RI Signal Applicability Assessment asks, scoped to whether the peer’s specific finding also describes us.
| Theme (from Section C) | Does this process/system exist in our operation? | Do we have evidence our own control is adequate, or is this untested? | Disposition | Linked applicability assessment / CAPA |
|---|---|---|---|---|
<<FILL>> | <<FILL: Yes/No>> | <<FILL>> | <<FILL: Applicable / Monitor / Not applicable>> | <<FILL>> |
Section E: Remediation timeline comparables
Where a peer’s warning letter has a close-out letter, the gap between the two dates is a rough real-world comparable for how long credible remediation of that theme actually took elsewhere. Use it to sanity-check your own CAPA target dates, not as a promise of your own timeline.
| Peer ref | Warning letter date | Close-out date (if issued) | Elapsed | Theme | Note |
|---|---|---|---|---|---|
<<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL: e.g. included a full facility requalification, not just a procedural fix>> |
Acceptance criteria
- The peer roster is selected against the stated criteria in Section A, with a written rationale for every peer, not an unscoped or headline-driven list.
- The roster is small enough to review every period and is itself reviewed on the defined cycle.
- Every enforcement item found for a roster peer has a gap comparison in Section D with a disposition, not left as an interesting fact with no follow-up.
- Applicable gap comparisons are linked to a real applicability assessment or CAPA reference, not closed inside this worksheet alone.
- Close-out timelines are used as directional comparables only, never presented as a guaranteed or typical remediation duration.
References
ICH Q9(R1), Quality Risk Management (informing risk identification with relevant historical and stakeholder information). ICH Q10, Pharmaceutical Quality System, Section 4 (external factors as a management review input).
Confirm the current source and posting status of any enforcement document cited before relying on it; treat this worksheet as an educational tool to adapt, not a compliance guarantee.
Revision history
| Version | Date | Author | Summary of change |
|---|---|---|---|
<<FILL: 1.0>> | <<FILL: date>> | <<FILL: author>> | Initial issue. |
Filled specimen (excerpt)
Illustrative worksheet for a fill-finish sterile injectables manufacturer. Peer names are role-based descriptors, not real companies; replace with your own tracked peers.
Section B, roster (excerpt):
| Peer ref | Descriptor | Jurisdictions tracked | Rationale |
|---|---|---|---|
| Peer A | Sterile injectable CDMO, comparable batch scale, two US sites | US, EU | Same modality and manufacturing model; public 483/WL history available |
| Peer B | Sterile injectable innovator, own-site manufacturing, single large US site | US | Same modality, different model (owns its own manufacturing); useful contrast case |
Section C, enforcement history (excerpt):
| Peer ref | Document type | Date | Cited regulation | Failure theme | Escalation | Close-out |
|---|---|---|---|---|---|---|
| Peer A | Warning Letter | 11 Apr 2026 | 211.113(b), 211.42 | Aseptic processing, environmental monitoring excursion not investigated | Warning Letter | Open (no close-out yet) |
| Peer B | 483 | 02 Jun 2026 | 211.192 | OOS invalidated without laboratory-phase justification | 483, EIR pending | N/A |
Section D, gap comparison (excerpt):
| Theme | Exists in our operation? | Evidence our control is adequate | Disposition | Linked reference |
|---|---|---|---|---|
| EM excursion not investigated | Yes, we run aseptic fill-finish | Self-check: last 6 months of EM excursion logs show 100% triggered an investigation record | Not applicable (control tested and evidenced) | Self-check ref SC-2026-041 |
| OOS invalidated without lab-phase justification | Yes, QC lab runs release testing | No recent self-check specific to this failure mode; general OOS SOP exists but has not been tested against this exact pattern | Applicable, targeted self-check ordered | RI-2026-063, applicability assessment pending |
The second row is the point of the exercise. The general OOS procedure existing is not the same as evidence it would survive the specific pattern the peer was cited for, and the worksheet forced that distinction instead of letting “we have an OOS SOP” stand in for “we tested against this exact failure mode.”
Common inspection findings this worksheet prevents
- A firm can describe general industry citation trends but cannot name a single comparable peer finding or say whether the same gap exists internally.
- Peer awareness stays anecdotal (something someone read about) rather than entering the applicability and CAPA process.
- The peer roster is either undocumented or so broad it was never actually reviewed each period.
- A remediation target date is set with no reference point for how long comparable remediation took elsewhere, and slips without an early warning.
How to adapt this worksheet
- Set your worksheet reference, parent SOP, and review cycle in the control block.
- Populate Section A with the dimensions that actually predict citation similarity for your modality; add a dimension if your product type has one not listed here.
- Keep the roster in Section B small enough to review every period; expand only if resourcing supports it.
- Route every Applicable disposition in Section D into your real applicability assessment and CAPA process, not just this worksheet.
- Update Section E only where a close-out letter genuinely exists; do not estimate a close-out date that was never issued.